Literature DB >> 8600343

Vincristine treatment triggering the expression of asymptomatic Charcot-Marie-Tooth disease.

Y Neumann1, A Toren, G Rechavi, B Seifried, N G Shoham, M Mandel, G Kenet, N Sharon, M Sadeh, R Navon.   

Abstract

A 16-year-old male suffering from Ewing's sarcoma of the pelvis was treated with vincristine as part of his chemotherapeutic protocol. The boy was never known to suffer from any neurological problems. His father had a mild limp, attributed to prolonged "taxi driving," that was never investigated medically. The first course of treatment, which included 2 mg of vincristine, resulted in clinical improvement. However, at the same time the patient developed severe weakness of both upper and lower limbs, areflexia, and gradually a pes cavus deformity. Nerve conduction studies were suggestive of severe peripheral sensorimotor neuropathy, axonal and demyelinative. A definite diagnosis of Charcot-Marie-Tooth was confirmed by molecular analysis showing the typical duplication of 1.5 megabases at 17 p11.2. This unique manifestation of vincristine neurotoxicity is reported and discussed.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8600343     DOI: 10.1002/(SICI)1096-911X(199604)26:4<280::AID-MPO12>3.0.CO;2-J

Source DB:  PubMed          Journal:  Med Pediatr Oncol        ISSN: 0098-1532


  11 in total

1.  Vincristine exacerbates asymptomatic Charcot-Marie-tooth disease with a novel EGR2 mutation.

Authors:  Tomonori Nakamura; Akihiro Hashiguchi; Shinsuke Suzuki; Kimiharu Uozumi; Shoko Tokunaga; Hiroshi Takashima
Journal:  Neurogenetics       Date:  2012-01-25       Impact factor: 2.660

2.  Vincristine induced cranial polyneuropathy.

Authors:  Ali Bay; Cahide Yilmaz; Nebi Yilmaz; Ahmet Faik Oner
Journal:  Indian J Pediatr       Date:  2006-06       Impact factor: 1.967

Review 3.  Peripheral neuropathy in children and adolescents treated for cancer.

Authors:  Kari L Bjornard; Laura S Gilchrist; Hiroto Inaba; Barthelemy Diouf; Marilyn J Hockenberry; Nina S Kadan-Lottick; Daniel C Bowers; M Eileen Dolan; Nicole J Ullrich; William E Evans; Kirsten K Ness
Journal:  Lancet Child Adolesc Health       Date:  2018-09-01

4.  Delayed Diagnosis of Metastatic Ewing Sarcoma Masked by Charcot-Marie-Tooth Disease.

Authors:  Ines B Menjak; Abha Gupta; Michelle N Grinman
Journal:  J Adolesc Young Adult Oncol       Date:  2013-12-01       Impact factor: 2.223

Review 5.  Vincristine-induced peripheral neuropathy in pediatric cancer patients.

Authors:  Erika Mora; Ellen M Lavoie Smith; Clare Donohoe; Daniel L Hertz
Journal:  Am J Cancer Res       Date:  2016-11-01       Impact factor: 6.166

6.  Vincristine treatment revealing asymptomatic hereditary motor sensory neuropathy type 1A.

Authors:  E Mercuri; J Poulton; J Buck; V Broadbent; M Bamford; H Jungbluth; A Y Manzur; F Muntoni
Journal:  Arch Dis Child       Date:  1999-11       Impact factor: 3.791

7.  Spinal MRI of vincristine neuropathy mimicking Guillain-Barré syndrome.

Authors:  Yun Woo Chang; Hye-Kyung Yoon; Jae Min Cho; Ki Woong Sung
Journal:  Pediatr Radiol       Date:  2003-09-13

8.  Sequencing of Charcot-Marie-Tooth disease genes in a toxic polyneuropathy.

Authors:  Andreas S Beutler; Amit A Kulkarni; Rahul Kanwar; Christopher J Klein; Terry M Therneau; Rui Qin; Michaela S Banck; Ganesh K Boora; Kathryn J Ruddy; Yanhong Wu; Regenia L Smalley; Julie M Cunningham; Nguyet Anh Le-Lindqwister; Peter Beyerlein; Gary P Schroth; Anthony J Windebank; Stephan Züchner; Charles L Loprinzi
Journal:  Ann Neurol       Date:  2014-09-17       Impact factor: 10.422

9.  Acute neurotoxicity following vincristine due to Charcot-Marie-Tooth disease in a young child with medulloblastoma.

Authors:  Trisha Kissoon; Sridharan Gururangan; John Sladky
Journal:  Neurooncol Pract       Date:  2019-03-18

10.  Unmasking a Case of Asymptomatic Charcot-Marie-Tooth Disease (CMT1A) With Vincristine.

Authors:  Roopam Jariwal; Basel Shoua; Katayoun Sabetian; Piruthiviraj Natarajan; Everardo Cobos
Journal:  J Investig Med High Impact Case Rep       Date:  2018-02-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.